PRQR
PRQR
NASDAQ · Biotechnology

Proqr Therapeutics Nv

$1.71
+0.09 (+5.56%)
As of Apr 1, 10:07 PM ET ·
Financial Highlights (FY 2026)
Revenue
17.54M
Net Income
-45,258,707
Gross Margin
Profit Margin
-258.1%
Rev Growth
+50.5%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 46.9% 46.9%
Operating Margin -265.8% -239.2% 5.6% 5.8%
Profit Margin -258.1% -245.2% 4.3% 4.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 17.54M 11.66M 53.79M 56.60M
Gross Profit 25.23M 26.55M
Operating Income -46,611,951 -27,883,520 2.99M 3.30M
Net Income -45,258,707 -27,074,002 2.31M 2.33M
Gross Margin 46.9% 46.9%
Operating Margin -265.8% -239.2% 5.6% 5.8%
Profit Margin -258.1% -245.2% 4.3% 4.1%
Rev Growth +50.5% +50.5% +4.8% +15.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 18.91M 18.91M 17.98M 18.29M
Total Equity 58.50M 58.50M 107.54M 109.94M
D/E Ratio 0.32 0.32 0.17 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -44,094,750 -27,843,145 4.13M 4.65M
Free Cash Flow 1.88M 2.75M